Background
==========

Activation of specific signaling pathways in lymphocytes determines the quality, magnitude and duration of immune responses. These pathways are also responsible for the induction, maintenance and exacerbation of physiological or pathological lymphocyte responses in transplantation, acute and chronic inflammatory diseases, and autoimmunity. The activation of T lymphocytes is triggered when the T-cell receptor (TCR) recognizes antigens presented by the major histocompatibility complex (MHC) in antigen-presenting cells \[[@B1]\]. Engagement of the TCR by antigen-MHC results in rearrangement of the actin cytoskeleton, induction of gene transcription, and progression into the cell cycle \[[@B2],[@B3]\]. The proximal events of TCR signaling include activation of the Src-family kinases Lck and Fyn, phosphorylation of TCR components, and activation of ZAP70 and Syk tyrosine kinases, as well as recruitment of adaptor molecules (LAT and SLP-76), which in turn couple to more distal signaling pathways including Ras and PLCγ \[[@B4],[@B5]\]. Using classical genetic and biochemical approaches, new components of the TCR signaling pathway are being discovered, albeit at a slow pace. Efficient identification of additional signaling molecules probably requires novel approaches.

Here, we describe our attempt to identify and validate novel signaling molecules specific for T-cell activation. We used up-regulation of the cell-surface marker CD69 in T cells to monitor TCR activation; CD69 as an activation marker has been well validated \[[@B6]\], more recently using T cells deficient in certain key signaling molecules such as SLP-76 and LAT \[[@B7],[@B8]\]. The rationale of this \'functional genomics\' screen was to identify cell clones whose CD69 upregulation was repressed following introduction of clones from a retroviral cDNA library. The library clones conferring such repression would then represent immune modulators that function to block TCR signal transduction.

Results
=======

Experimental design
-------------------

Jurkat Clone 4D9 was selected for low basal levels of CD69 expression and strong induction following TCR stimulation (see Additional data file 1 for details of the selection and infection procedures). The \'Tet-off\' system was adapted for regulated expression of the retroviral cDNA library: cDNA inserts in the retroviral library were cloned behind the tetracycline (Tet) regulatory element (TRE) and the cytomegalovirus (CMV) minimal promoter. Transcription of the cDNA inserts was then dependent on the presence of tetracycline-controlled transactivator (tTA) \[[@B9]\], a fusion of Tet repression protein and the VP16 activation domain, and the absence of tetracycline or its derivatives such as doxycycline (Dox). A derivative of Jurkat clone 4D9 stably expressing tTA, called 4D9\#32, was engineered and selected (see Additional data file 1).

As a positive control for this functional genetic screen, we tested dominant-negative forms of ZAP70, which are known to inhibit TCR signaling \[[@B10]\]. We subcloned a kinase-inactive ZAP70 (ZAP70 KI) and a truncated ZAP70, comprising only the two Src homology 2 (SH2) domains and referred to here as ZAP70 SH2 (N+C), into the bicistronic retroviral vector under TRE control followed by the internal ribosome entry site (IRES) coupled to green fluorescent protein (GFP; see Figure [1a](#F1){ref-type="fig"}). Both ZAP70 SH2 (N+C) and ZAP70 KI inhibited TCR-induced CD69 expression (Figure [1b](#F1){ref-type="fig"}). Consistent with previous reports using transiently overexpressed ZAP70 constructs \[[@B10]\], the truncated ZAP70 protein inhibited anti-TCR-induced CD69 expression more strongly than the ZAP70 KI protein did (Figure [1b](#F1){ref-type="fig"}). The CD69-inhibitory phenotype was dependent on expression of dominant-negative forms of ZAP70. When Dox was added before TCR stimulation, there was no inhibition of CD69 expression (Figure [1c](#F1){ref-type="fig"}, right panels). Fluorescence-activated cell sorting (FACS) analysis of cellular expression of GFP revealed a lack of GFP-positive cells (Figure [1c](#F1){ref-type="fig"}, left panels), suggesting that the bicistronic ZAP70 SH2 (N+C)-IRES-GFP mRNA was not transcribed. A lack of expression of the ZAP70 SH2 (N+C) protein in the presence of Dox was confirmed by western blotting (Figure [1d](#F1){ref-type="fig"}). Collectively, these results indicated that Jurkat clone 4D9\#32 was suitable for screening for inhibitors of anti-TCR-induced CD69 expression.

Screening for cells lacking CD69 upregulation
---------------------------------------------

The scheme to obtain cell clones with a CD69-inhibitory phenotype is shown in Figure [2a](#F2){ref-type="fig"}. Jurkat 4D9\#32 cells were infected with the pTRA-cDNA libraries made from human lymphoid organs such as thymus, spleen, lymph node and bone marrow (see Additional data file 2 for details of construction and assessment of the pTRA-cDNA libraries). After library infection, cells were stimulated with the anti-TCR antibody C305 overnight. A total of 7.1 × 10^8^cells were stained with anti-CD69 antibody conjugated to allophycocyanin (APC) and anti-CD3 antibody conjugated to phycoerythrin (PE), and then screened using flow cytometry. There was a significant reduction of the CD3-TCR complex on the cell surface as compared to unstimulated cells, as a result of receptor-mediated internalization, but we were nevertheless able to distinguish the CD3^-^ population from the CD3^+^(CD3^low^and CD3^high^) populations (see Additional data file 3 for the distinction between CD3^-^, CD3^low^and CD3^high^cell populations). We consistently observed that more than 2% of the cells had lost TCR-CD3 complex on the surface, causing them to be unresponsive to stimulation and, consequently, to have low CD69 expression (circled region R1 in Figure [2b](#F2){ref-type="fig"}). We therefore collected by high-speed flow sorter only cells with the lowest CD69 expression that still retained CD3 expression. We termed the desired phenotype CD69^low^CD3^+^(Figure [2a](#F2){ref-type="fig"}), and it represented 1% of the total stained cells (boxed region R2 in Figure [2b](#F2){ref-type="fig"}). The 1% sorting gate also translated as 100-fold enrichment in the first round of sorting. In subsequent rounds of sorting, the sorting gate R2 was always maintained to capture the equivalent of 1% of the control cells that were stimulated but were never flow-sorted. As shown in Figure [2b](#F2){ref-type="fig"}, we achieved significant enrichment after three rounds of reiterative sorting; cells with the desired CD69^low^CD3^+^phenotype increased from 1% to 23.2% of the population. In addition, the overall population\'s geometric mean for the CD69 fluorescent intensity was also reduced (from \> 300 to 65).

Given our experimental design, we expected the expression of retroviral cDNAs and their putative inhibitory effect to be turned off with the addition of Dox. This feature helped us to ascertain that the phenotype was due to expression of the cDNA library rather than to epigenetic changes or spontaneous or retroviral-insertion-mediated somatic mutation(s). To confirm this, we compared anti-TCR-induced CD69 expression in the presence and absence of Dox. As shown in Figure [2c](#F2){ref-type="fig"}, cells with the CD69^low^CD3^+^ phenotype decreased from 24.0% to 13.0% with the addition of Dox, demonstrating that a significant number of cells (11%) had lost the CD69^low^CD3^+^phenotype when library-cDNA expression was turned off. These data suggested that the CD69^low^CD3^+^phenotype in a significant proportion (at least 11% out of 24%, or 45.8%) of cells in this population was indeed caused by expression of the cDNA-library clones.

Functional analysis of single-cell clones
-----------------------------------------

Next, we deposited single cells into 96-well plates in conjunction with the fourth and subsequent rounds of sorting for the CD69^low^CD3^+^ phenotype. The phenotype of each single-cell clone was characterized by growing the cells in the absence and presence of Dox. A few examples of the Dox-regulatable phenotypes for individual clones are shown in Figure [3a](#F3){ref-type="fig"}. Dox regulation of CD69 expression was expressed as the ratio of CD69 geometric mean fluorescent intensity in the presence of Dox divided by the CD69 geometric mean fluorescent intensity in the absence of Dox after TCR stimulation; we termed this ratio the \'Dox ratio\'. In uninfected or mock-infected cells, Dox had little or no effect on the induction of CD69 expression, with mean Dox ratios for individual clones of 1.00 ± 0.25 (standard deviation). We used twice the standard deviation above the mean as a cut-off criterion and regarded clones with a ratio above 1.5 as Dox-regulated clones. Out of 2,828 clones analyzed, 1,323 had a Dox-regulatable phenotype, representing 46.8% of analyzed clones. This percentage was comparable to the percentage based on the overall population (46.8% compared to 45.8%), suggesting that the single-cell clones constituted a fair representation of the entire population. The distribution of Dox ratios among all 2,828 clones is shown in Additional data file 4.

The cDNA inserts of selected clones with a Dox-regulatable phenotype were recovered by RT-PCR using primers specific for the vector sequence flanking the cDNA library insert (Figure [3b](#F3){ref-type="fig"}). Most clones generated only one RT-PCR product, but a few clones generated two or more products. Sequencing analysis revealed that the additional RT-PCR products were usually caused by double or multiple insertions of retroviruses. The results of the cDNA analysis are summarized in Table [1](#T1){ref-type="table"}.

Characterization of proteins critical for T-cell activation
-----------------------------------------------------------

As shown in Table [1](#T1){ref-type="table"}, we obtained known TCR regulators such as Lck, ZAP70, Syk, PLCγ1, PAG, SHP-1/PTP1C, Csk and nucleolin (reviewed in \[[@B11]\]). The hits with the highest frequency, however, were those encoding the TCR β subunit. This new β chain leads to the assembly of a new TCR complex no longer recognizable by the stimulating antibody C305, because C305 only recognizes the original endogenous Jurkat clonotypic TCR complex \[[@B2]\] (see also Additional data file 5).

Among the known T-cell activation regulators, we obtained two ZAP70 hits containing the endogenous ATG initiation codon, missing the catalytic domain and ending at amino acids 262 and 269, respectively (Figure [4a](#F4){ref-type="fig"}). The deletions closely mirror the positive control for the screen, ZAP70 SH2 (N+C), which ended at amino acid 276 and has been shown to be a dominant-negative protein \[[@B10]\]. Similarly, we obtained a kinase-truncated form of Lck (Figure [4b](#F4){ref-type="fig"}) that caused inhibition of CD69, mimicking the phenotype of a Jurkat somatic mutant lacking Lck \[[@B12]\]. These clones represent dominant-negative forms of kinases required for T-cell activation. The inhibitory effects of these and other clones were confirmed by subcloning them into the pTRA-IRES-GFP vector, reintroducing into the naïve Jurkat-tTA cells, and comparing the CD69 expression in GFP-positive and GFP-negative cells upon TCR stimulation (Figure [4](#F4){ref-type="fig"}).

TCR engagement leads to rapid tyrosine phosphorylation and activation of PLCγ1 \[[@B13]\]. One of our hits contained the pleckstrin homology (PH) domain and the amino- and carboxy-terminal SH2 domains of PLCγ1 (Figure [4c](#F4){ref-type="fig"}). Significantly, this hit also lacked the crucial tyrosine Y783, which is essential for coupling of TCR stimulation to IL-2 promoter activation. The Y783F mutant is a very potent dominant-negative form of PLCγ1 \[[@B14]\]. Indeed, the original clone encoding the PLCγ1 hit had the highest Dox ratio for CD69 expression among all clones analyzed. When introduced into naïve Jurkat cells, this fragment also caused a severe block of TCR-induced CD69 expression (Figure [4c](#F4){ref-type="fig"}).

In addition to known signaling molecules, we also discovered genes whose sequences had been reported previously but whose involvement in TCR signaling was not documented (Table [1](#T1){ref-type="table"}, and see Additional data files 6 and 7). EDG1 (endothelial differentiation gene-1) was discovered initially from a set of immediate-early-response gene products cloned from human umbilical vein endothelial cells \[[@B15]\]. EDG1 is a G-protein-coupled receptor (GPCR) with high affinity for sphingosine 1-phosphate (S1P) \[[@B16]\]. Although EDG1 has been reported to link to multiple signaling pathways \[[@B17]\], no role in TCR signaling had been documented. From our genetic screen, we obtained two carboxy-terminal truncation EDG1 mutants. Reintroducing EDG1 Hit 1 into naïve Jurkat cells conferred a CD69-inhibition phenotype (Figure [4d](#F4){ref-type="fig"}). We believe the EDG1 hits may work as constitutively active forms of the endogenous protein, given that overexpressing full-length EDG1 also caused inhibition of CD69 expression (data not shown).

PAK (p21-activated kinase) proteins are critical effectors that link Rho-family GTPases, such as Cdc42 and Rac1, to cytoskeletal reorganization and nuclear signaling \[[@B18],[@B19]\]. PAK proteins constitute a family of serine/threonine kinases that utilizes the CRIB (Cdc42/Rac interactive binding) domain to bind to small GTPases; members of the family include PAK1, PAK2, PAK3 and PAK4 \[[@B19]\]. Among the four PAK proteins, PAK2 (also known as PAK65 \[[@B20]\] and gamma-PAK \[[@B21]\]) is activated by proteolytic cleavage during caspase-mediated apoptosis \[[@B22]\]. The role of PAK2 in Jurkat T cells has been reported primarily to be in membrane and morphological changes in apoptotic cells \[[@B23]\]. PAK1, on the other hand, has been reported to be involved in T-cell signaling \[[@B24],[@B25]\]. Interestingly, we identified two different truncated versions of PAK2, both lacking the kinase domain, in our functional genetic screens with the fourth highest frequency (after TCRβ, ZAP70 and TCPTP; see Table [1](#T1){ref-type="table"}). We further demonstrated that these dominant-negative forms of PAK2 also confer CD69 inhibition when introduced into naïve Jurkat cells (Figure [4e](#F4){ref-type="fig"} and Table [1](#T1){ref-type="table"}).

An interesting adaptor molecule cloned from our genetic screen is Grb7 (Figure [4f](#F4){ref-type="fig"}). Like Grb2, Grb7 was originally cloned by screening bacterial expression libraries with the tyrosine-phosphorylated carboxyl terminus of the epidermal growth factor (EGF) receptor \[[@B26]\]. The Grb7 family of proteins - Grb7, Grb10, and Grb14 - share significant sequence homology and a conserved molecular architecture \[[@B27]\]. Their functional domains include a proline-rich region, an RA (RalGEF/AF6 or Ras-associating) domain, a PH domain and an SH2 domain. Like other adaptor molecules, Grb7 family proteins function to mediate the coupling of multiple cell-surface receptors to downstream signaling pathways in the regulation of various cellular functions. Our identification of a strong phenotype for the Grb7 SH2 domain in TCR signal transduction suggests that Grb7 may be an important immune-regulatory molecule (Figure [4f](#F4){ref-type="fig"}).

We also discovered an uncharacterized molecule whose sequence in GenBank was assembled from expressed sequence tag (EST) data. This novel molecule, FLJ20456, was renamed by us as TRAC-1, for T-cell RING protein in activation. As shown in Figure [4g](#F4){ref-type="fig"}, TRAC-1 has a RING finger domain, which is characteristically found in a class of proteins collectively called ubiquitin ligases or E3s \[[@B28]\]. Members of the Cbl protein family are the best-known E3s involved in the regulation of TCR signaling \[[@B29]\]. T cells manifest enhanced signaling in both *c-Cbl*and *Cbl-b*mutant mice, suggesting that the wild-type function of these proteins is in negatively regulating T-cell activation. More recently, Cbl proteins have been shown to function as RING finger E3s so as specifically to target activated receptors and protein-tyrosine kinases for ubiquitination and therefore to down-regulate their signaling \[[@B30]\]. The TRAC-1 hit we obtained has a truncation in the carboxyl terminus but still retains the intact RING finger domain (Figure [4g](#F4){ref-type="fig"}). Reintroducing the TRAC-1 hit into naïve Jurkat cells caused strong inhibition of the anti-TCR-induced CD69 expression in infected cells.

For a complete characterization of the functional genetic screen, as well as additional selected hits, see Additional data files 6 and 7.

Gene expression in tissues and primary lymphocytes
--------------------------------------------------

We studied the expression profiles of EDG1, PAK2, Grb7 and TRAC-1 by northern blot analysis. We detected ubiquitous expression of EDG1 and PAK2 in normal human tissues, including thymus, spleen and peripheral blood lymphocytes (PBL; Figure [5a](#F5){ref-type="fig"}). Grb7 has strong expression in kidney and placenta, but little or no expression in thymus or PBL by northern blot analysis (Figure [5b](#F5){ref-type="fig"}). Interestingly, TRAC-1 has a highly specific expression in organs associated with the lymphoid system or hematopoietic system, such as spleen, liver and PBL (Figure [5b](#F5){ref-type="fig"}). We also detected a faster-migrating band with the TRAC-1 probe in placenta, perhaps representing an alternatively spliced message.

We further examined expression of these selected genes in lymphocyte subsets isolated from healthy human peripheral blood using semi-quantitative RT-PCR. As shown in Figure [5c](#F5){ref-type="fig"}, EDG1 expression was detected in both T cells (higher expression in CD4^+^than in CD8^+^T cells) and B cells (CD19^+^), but not in monocytes (CD14^+^). Its expression level in T and B cells was not affected upon mitogenic activation. EDG1 was also detected in the brain. PAK2 was detected in resting and activated lymphocytes as well as in the placenta (Figure [5d](#F5){ref-type="fig"}). Even though Grb7 was not detected in the PBL by northern blot, it was detected in peripheral blood mononuclear cells (PBMC) using the more sensitive RT-PCR method (Figure [5e](#F5){ref-type="fig"}). Grb7 expression seemed to be slightly increased upon activation. Consistent with the northern blot profile, TRAC-1 was detected only in lymphocytes and not in the placenta (Figure [5f](#F5){ref-type="fig"}). In summary, all four genes are expressed in the lymphoid system, supporting their potential physiological role in lymphocyte signaling.

Function in primary T lymphocytes
---------------------------------

The relevance of the cDNA hits from our screen to the physiological functions of T cells was investigated in primary T lymphocytes. We subcloned the hits into a retroviral vector under the control of a constitutively active promoter embedded in the retroviral long terminal repeat (LTR), followed by IRES-GFP \[[@B31]\]. We then developed a protocol to couple successful retroviral infection to subsequence T-cell activation. As shown in Figure [6a](#F6){ref-type="fig"} (left panels), fresh PBL contained both T cells and B cells. The combined CD4^+^and CD8^+^cells represented T cells (about 81% of total lymphocytes in this particular donor). The remaining 19%, which were CD4^-^CD8^-^cells, were B cells as stained by CD19 (data not shown). Upon culturing with anti-CD3 and anti-CD28 antibodies, primary T lymphocytes were expanded and primary B cells and other cell types gradually died off (Figure [6a](#F6){ref-type="fig"}, right panels). Importantly, primary T lymphocytes were successfully infected by retroviruses (Figure [6a,b](#F6){ref-type="fig"}).

As seen with Jurkat cells (data not shown), GFP translated by way of IRES was not as abundant as GFP translated using the conventional Kozak sequence (comparing GFP geometric mean from CRU5-IRES-GFP to that from CRU5-GFP). Nevertheless, the percentage infection remained similar (Figure [6b](#F6){ref-type="fig"}; 32.4% and 31.3% respectively). Insertion of a gene in front of IRES-GFP further reduced the expression level of GFP (Figure [6b](#F6){ref-type="fig"}), a trend observed with many other cell lines (data not shown). After allowing cells to rest for 5 days following infection, we flow-sorted cells into two populations: GFP-negative and GFP-positive. Exact numbers of sorted cells were immediately put into culture. As seen in Figure [6c](#F6){ref-type="fig"}, resting cells did not produce IL-2, nor did cells stimulated with anti-CD3 alone. Anti-CD3 plus anti-CD28 induced robust IL-2 production in the CIG vector-infected cells (CIG), regardless of the GFP expression (note the different scales of the upper graphs compared to the lower ones).

These observations are consistent with previous reports on freshly isolated primary T lymphocytes and also indicate that prior culture and retroviral infection did not change the basic properties of these primary T lymphocytes. Addition of anti-CD28 in conjunction with anti-CD3 also led to high IL-2 production from the GFP-negative population of cells infected with CIG-LCK, -PLCγ1, -EDG1 and -PAK2 hits. The GFP-positive population from these cells was, however, significantly impaired in IL-2 production following anti-CD3 and anti-CD28 stimulation (Figure [6c](#F6){ref-type="fig"}). As expected, the defect caused by the Lck, PLCγ1, EDG1 and PAK2 hits can be completely rescued by stimulation using PMA and ionomycin (Figure [6c](#F6){ref-type="fig"}). Taken together, these results show that Lck and PLCγ1 play a crucial role in IL-2 production from primary T lymphocytes, consistent with their involvement in membrane-proximal signaling events of T-cell activation. More importantly, our results document for the first time the involvement of the seven-transmembrane molecule EDG1 and the serine/threonine kinase PAK2 in physiological functions of T cells. Together, the results also demonstrate a rapid system for further validating hits from functional genetic screens using primary lymphocytes.

Discussion
==========

In this article, we report a large-scale functional genetic screen for inhibitors of TCR signaling. We isolated many known signaling molecules - such as Lck, ZAP70, Syk, PLCγ1 - as novel truncation mutants (probably created during library preparation) with dominant-negative effects. In addition, we also discovered molecules previously unknown to this pathway, including transmembrane molecules (EDG-1, IL-10Rα and integrin α~2~), cytoplasmic enzymes and adaptors (PAK-2, A-Raf-1, TCPTP, Grb7, SH2-B and GG2-1), and cytoskeletal molecules (moesin and vimentin; see Table [1](#T1){ref-type="table"}). Of note, we also identified a novel molecule, TRAC-1, which had lymphoid and hematopoietic specific expression (Figure [5b](#F5){ref-type="fig"}).

We showed that EDG1, PAK2, and Grb7, genes originally described in different contexts, are also expressed in lymphocytes (Figure [5](#F5){ref-type="fig"}). This is not unexpected, since the retroviral cDNA libraries were generated using mRNA from human lymphoid organs such as thymus, spleen, lymph nodes and bone marrow. Our expression data are generally consistent with those published by other investigators. For example, EDG1 was reported to be expressed in human natural killer cells \[[@B32]\] and dendritic cells \[[@B33]\]. PAK2 is expressed ubiquitously in human tissues \[[@B20]\] and in Jurkat cells \[[@B22]\]. Grb7 has a broad expression in human (pancreas, placenta, kidney, prostate and small intestines) \[[@B34]\]. Grb7 was not easily detectable by northern blot in thymus, spleen and PBL, but its expression was detected in specific lymphocyte subsets (Figure [5e](#F5){ref-type="fig"}). This indicates that our screen is capable of identifying genes with potentially important roles in lymphocyte activation whose expression is not limited to the lymphoid system. The fact that these genes\' expression is not limited to the lymphoid system does not diminish the potential role they could play in lymphocyte activation. For example, the Ras-Raf-MAP kinase pathway is ubiquitously present in many tissues and cell types, as well as conserved evolutionarily, but this pathway has also been shown to be important in lymphocyte signaling.

In the \'post-genomics\' era, the novelty of discovery lies in assigning novel functions to gene products. In our screens, for example, we identified two hits representing cytoplasmic truncated versions of EDG-1, a receptor for S1P \[[@B16]\]. Interestingly, FTY720, a potent immunosuppressant in advanced clinical development, has been shown to act through EDG-1 and S1P signaling pathways \[[@B35],[@B36]\]. The fact that truncated EDG-1 proteins were identified in our T-cell activation screen suggests potential intersections of the TCR signaling pathway and the S1P signaling pathway, as well as new insights into the mechanisms of action of FTY720.

Our results also call for attention to potential differences between related family members. For example, PAK-1 (instead of PAK-2), c-Raf-1 (instead of A-Raf-1) and Grb2 (instead of Grb7) have been reported to be associated with the TCR signal transduction pathway \[[@B25],[@B37]-[@B40]\]. Our functional genetic screens identified PAK2, A-Raf-1, and Grb7 as important regulators of TCR-induced CD69 expression. It is possible that the dominant-negative proteins we cloned also inhibit other related family members. Alternatively, it is equally possible that the previously reported dominant-negative forms of PAK1, c-Raf-1, and to a lesser extent, Grb2, may have inhibited PAK2, A-Raf-1 and Grb7, respectively. In fact, binding of the human immunodeficiency virus (HIV) Nef protein and subsequent activation of the PAK-related kinase and phosphorylation of its substrate can be readily detected in both infected primary T lymphocytes and macrophages \[[@B41]\]. When the HIV-Nef-associated kinase was characterized carefully, it became clear that this kinase was PAK2 and not PAK1 \[[@B42],[@B43]\]. This example supports the notion that PAK2 could be the more relevant kinase in T-cell signaling. Of course, it is entirely possible that these related family members are not mutually exclusive in participating in the TCR signal-transduction pathway.

In conclusion, we have demonstrated a successful approach for discovering and validating, in a functionally relevant context, important immune regulators on a genome-wide scale. This approach provides a tool for functional cloning of regulators in numerous signal-transduction pathways \[[@B44],[@B45]\]. For example, B-cell activation-induced CD69 expression \[[@B46]\] and, recently, the IL-4-induced immunoglobulin E class switch \[[@B47]\], have also been shown to be amenable to genetic perturbation following introduction of retroviral cDNA or random cyclic peptide libraries. Importantly, the outlined strategy, which requires no prior sequence information of the players involved, does not bias the search to previously known signaling molecules, molecules flagged by DNA-array technologies, or signaling molecules discovered in other contexts. This approach has added to the list of potential players in T-cell biology that have not been identified in other standard pathway-mapping techniques.

Materials and methods
=====================

Preparation of cDNA libraries
-----------------------------

The mRNA extracted from human lymph nodes, thymus, spleen and bone marrow was used to produce two randomly primed cDNA libraries. For one library (-ATG) inserts were directionally cloned and the second (+ATG) non-directionally cloned and provided with three exogenous ATGs in three frames. The resulting cDNAs were cloned into the pTRA-exs vector \[[@B48]\] for doxycycline-(Dox-) regulatable expression in cell lines expressing the tetracycline transactivator protein (tTA) \[[@B9]\]. The total combined complexity of the two pTRA-cDNA libraries was 5 × 10^7^independent clones.

Cell lines
----------

Phoenix A cells were cultured in DMEM supplemented with 10% fetal calf serum (FCS), penicillin and streptomycin. Human T-cell leukemia line Jurkat was obtained from Novartis (Vienna, Austria) and was cultured in RPMI 1640 medium supplemented with 10% FCS, penicillin and streptomycin. Clone 4D9 with an optimal CD69 induction was obtained after sequential FACS-sorting for low basal CD69 expression and high induction of CD69 expression following TCR stimulation. To produce the Jurkat-tTA cell line, Clone 4D9 was infected with a reporter construct which expresses Lyt2 driven by a tetracycline responsive element (TRE) and a retroviral construct, CtTA1H, which constitutively expresses tTA \[[@B48]\]. The Jurkat-tTA cell clone 4D9\#32 was obtained by sorting for high Lyt2 expression in the absence of Dox and low expression of Lyt2 in the presence Dox (10 ng/ml).

Transfection and infection
--------------------------

Phoenix A packaging cells were transfected with retroviral vectors using calcium phosphate for 6 h following standard protocols \[[@B49]\]. After 24 h, supernatant was replaced with complete RPMI medium and virus was allowed to accumulate for 24 h at 32°C. Viral supernatant was collected, filtered through a 0.2 μM filter and mixed with Jurkat cells or human primary T lymphocytes at a density of 5 × 10^5^cells per ml. Cells were spun at room temperature for 3 h at 2,500 rpm, followed by overnight incubation at 37°C. Transfection and infection efficiencies were monitored by FACS. Functional analysis was carried out at least 2 days after infection.

Stimulation
-----------

For CD69 upregulation experiments, Jurkat cells were split to 2.5 × 10^5^ cells per ml 24 h prior to stimulation. Cells were spun and resuspended at 5 × 10^5^cells per ml in fresh complete RPMI medium in the presence of 300 ng/ml C305 (anti-Jurkat clonotypic TCR) hybridoma \[[@B2]\] supernatant, 100 ng/ml OKT3 (anti-CD3), 100 ng/ml SpvT3 (anti-CD3), or PMA (5 ng/ml) for 20-26 h at 37°C, and then assayed for surface CD69 expression.

Antibodies and flow cytometry
-----------------------------

Jurkat cells or human peripheral blood lymphocytes were stained with FITC-conjugated monoclonal anti-mouse CD8α (Lyt2), APC-conjugated mouse monoclonal anti-human CD3, anti-human CD8, or anti-human CD69 antibodies, and PE-conjugated mouse monoclonal anti-human CD3 or anti-CD4 antibodies (all from Caltag, Burlingame, USA) at 4°C for 20 min and analyzed using a FACSCalibur instrument (Becton Dickinson, Franklin Lakes, USA) with the CellQuest software. Fluorescent-activated cell sortings were performed on the MoFlo instruments (Cytomation, Fort Collins, USA).

Genetic screens
---------------

Phoenix A packaging cells were transfected with pTRA-cDNA libraries. Supernatant containing packaged viral particles was used to infect 3.5 × 10^8^Jurkat-tTA cells with an efficiency of 52% based on parallel infection with TRA-GFP \[[@B48]\]. After 4 days of cDNA expression, library-infected cells were stimulated with 300 ng/ml C305 for 20-30 h, stained with APC-conjugated anti-CD69 and PE-conjugated anti-CD3, and 1% of total cells with the desired CD69^low^CD3^+^phenotype were isolated using MoFlo. Sorting was repeated multiple times with a 6-day rest period between stimulations until the population was significantly enriched for the desired CD69^low^CD3^+^phenotype. Single cells were deposited to 96-well plates and expanded in the presence and absence of Dox, stimulated and analyzed for CD69 upregulation.

Isolation of cDNA inserts
-------------------------

PCR primers were designed to specifically amplify the inserts from pTRA-cDNA libraries. The primers contained flanking *Bst*XI sites for subsequent cloning to the pTRA-IRES-GFP and CRU5-IRES-GFP vectors \[[@B48],[@B50]\]. BstXTRA5G: 5\'-TTGCAGAACCACCACCTTGGGCTCTTAACCTAGGCCGATC-3\'. BstXTRA3D: 5\'-TTGCAGAACCAATTTAATGGCGGCCAGTCAGGCCATCGTCG-3\'. RT-PCR cloning was achieved with kits from Clontech (Palo Alto, USA) or Life Technologies (Carlsbad, USA). The gel-purified RT-PCR fragments were sequenced as well as digested with *Bst*XI for subcloning into the retroviral pTRA-IRES-GFP or CRU5-IRES-GFP vectors.

Semi-quantitative PCR analysis
------------------------------

Human Blood Fractions MTC panel (Clontech) with normalized, first-strand cDNA preparations from RNA of various purified cells were used as templates. CD19^+^cells were activated with 2 μl/ml pokeweed mitogen for 4 days, mononuclear cells with 2 μl/ml pokeweed mitogen and 5 μg/ml concanavalin A for 3 days, CD4^+^cells with 5 μg/ml concanavalin A for 3-4 days, and CD8^+^cells with 5 μg/ml phytohemagglutinin for 3 days. The following primers were used to amplify various cDNA fragments: EDG1: forward primer 5\'-GCAAGAACATTTCCAAGGCCAGCC-3\', reverse primer 5\'-GGGTGTGGGATGTACAGGGCATCC-3\', 35 cycles; PAK2: forward primer 5\'-CGGAGAACTGGAAGATAAGCCTCC-3\', reverse primer 5\'-AAAGCCAACATGGATGGTGTGCTC-3\', 35 cycles; Grb7: forward primer 5\'-ATGCCCACTGACTTCGGTTT-3\', reverse primer 5\'-GATCCGAAGCCCCTTGTGT-3\', 40 cycles; TRAC-1: forward primer 5\'-TTACACCAGCCTGTCCGGA-3\', reverse primer 5\'-CAGACTGGTAGCAATACAGGAACG-3\', 35 cycles.

Commercially available primers were used for GAPDH (PerkinElmer, Wellesley, USA) and β-actin (Clontech), 25 cycles. The PCR products were then electrophoresed on agarose/ethidium bromide gels.

Northern blot analysis
----------------------

Human Multiple Tissue Northern Blots were purchased from Clontech. The following probes were used: EDG1, base pairs 1-1,023 of its open reading frame; PAK2, base pairs 1-341 of its open reading frame; Grb7, base pairs 1,268-1,599 of its open reading frame; and TRAC-1, base pairs 1-509 of its open reading frame.

Culture and infection of primary T lymphocytes
----------------------------------------------

Commercially available primary blood mononuclear cells (PBMC; AllCells LLC, Berkeley, USA) were cultured in RPMI + 10% FCS for 1-2 h in tissue culture flasks to allow macrophages and other adhering cells to settle down. The suspended cells were cultured with anti-CD3 (30 ng/ml) and anti-CD28 (100 ng/ml) for 2 days to allow T cells to expand and other cell types to gradually die off. These primary T lymphocytes were infected with 1 ml retroviral supernatant in a 24-well plate. One day after infection, 1 ml spent medium from the bulk culture was added to each well. The cells were further expanded for a few days with addition of fresh RPMI + 10% FCS. Such an expansion also allowed the cells to return to the resting state with low CD69, CD25, and CD40L expression. Cells were then sorted by FACS, on the basis of GFP expression, directly into a round bottom 96-well plate coated with anti-CD3 alone, anti-CD3 + anti-CD28, or not coated. To the uncoated wells, PMA (5 ng/ml final) and ionomycin (1 μM final) were added. Then, 40 h later, supernatants were harvested for IL-2 measurement using commercial reagents (R&D Systems, Minneapolis, USA).

Additional data files
=====================

The following are provided as additional materials: details of the selection and infection of Jurkat clone 4D9 (Additional data file [1](#s1){ref-type="supplementary-material"}); construction of the pTRA-cDNA libraries and assessing the efficiency of infection (Additional data file [2](#s2){ref-type="supplementary-material"}); distinction between CD3^-^, CD3^low^and CD3^high^cell populations (Additional data file [3](#s3){ref-type="supplementary-material"}); distribution of Dox ratios among the 2,828 single-cell clones analyzed (Additional data file [4](#s4){ref-type="supplementary-material"}); details of clones with TCRβ hits (Additional data file [5](#s5){ref-type="supplementary-material"}); a summary of the genetic screen for inhibitors of TCR-induced CD69 expression (Additional data file [6](#s6){ref-type="supplementary-material"}); characterization of additional hits from the T-cell activation screen (Additional data file [7](#s7){ref-type="supplementary-material"}); correlation of the CD69 inhibitory phenotype with the cDNA expression level (Additional data file [8](#s8){ref-type="supplementary-material"}).

Supplementary Material
======================

###### Additional data file 1

**(a)** Jurkat cells were stimulated with anti-TCR antibody C305 for 24 h and then stained with anti-CD69-APC and analyzed on a FACSCalibur. The dashed line indicates CD69 level before stimulation and the solid line after stimulation. **(b)** A diagram of the TRA-Lyt2 construct and the Dox-off system. **(c)** A Jurkat clone (4D9) with optimal CD69 expression profile was infected with pTRA-Lyt2 and a retroviral construct that constitutively expresses tTA to obtain the Jurkat-tTA cell clone 4D9\#32. The solid line indicates Lyt2 level with Dox (10 ng/ml) and the dashed line without Dox, in clone 4D9\#32.

###### 

Click here for additional data file

###### Additional data file 2

**(a)** Diagram of the retroviral library vector used to make the pTRA-cDNA libraries (top) and after it has stably integrated into the genome (bottom). **(b)** Efficiencies of transfection (top panels) and infection (bottom panels). Phoenix A cells were transfected with TRA-GFP in parallel to the pTRA-cDNA libraries; 24 h later, TRA-GFP-transfected Phoenix A cells were analyzed for GFP expression by FACS. The percentage of GFP-positive cells (66%) from TRA-GFP-transfection was taken as the efficiency of library transfection (top left panel: mock-transfected Phoenix A cells; top right panel: TRA-GFP-transfected Phoenix A cells). Two days after transfection, the viral supernatant harboring pTRA-cDNA libraries or TRA-GFP were used to infect Jutkat-tTA cells (clone 4D9\#32) in parallel. Then, 60h after infection, TRA-GFP-infected Jurkat-tTA cells were analyzed for GFP expression by FACS. The percentage of GFP-positive cells (52%) from TRA-GFP-infection was taken as the efficiency of library infection (bottom left panel: mock-infected Jurkat-tTA cells; bottom right panel: TRA-GFP-infected Jurkat-tTA cells).

###### 

Click here for additional data file

###### Additional data file 3

Stimulation of Jurkat cells with anti-TCR antibody (C305) reduced cell surface expression of CD3. Jurkat-tTA cells were stained with anti-CD3-PE antibody before and after overnight stimulation with C305 (300 ng/ml). The dashed line indicates the CD3 level of unstimulated cells and the solid line the CD3 level of stimulated cells. TCR stimulation reduced cell-surface expression of CD3, as expected for antibody-mediated receptor internalization \[52\]. Importantly, it was possible to separate the cells expressing a low level of CD3 after stimulation (CD3^low^) from those not expressing CD3 at all (CD3^-^); both unstimulated and stimulated Jurkat-tTA cells have a minor population (around 2%) of CD3^-^ cells.

###### 

Click here for additional data file

###### Additional data file 4

**(a)** Distribution of the Dox ratio (limited to between 1.5 to 10) among 1,186 cell clones. A total of 2,828 cell clones selected based on the CD69^low^CD3^+^ criteria of the T-cell activation screen were assayed for CD69 expression after stimulation in the presence or absence of Dox, resulting in 1,323 clones with a Dox-regulatable phenotype. CD69 geometric mean fluorescent intensity in the presence of Dox was divided by that in the absence of Dox to give rise to the Dox ratio for each individual clone. The majority of Dox-regulatable clones had a Dox ratio between 1.5 and 10 (1,186 clones out of 1,323, or 89.6%). **(b)** Distribution of Dox ratios among all 2,828 cell clones is shown using the number of clones on the *y* axis and the Dox ratio on the *x* axis. The mean Dox ratio for the 2,828 clones was 3.02 ± 10.38 (standard deviation). There were rare clones with a Dox ratio up to 70. These few clones with high Dox ratios contributed to the higher standard deviation for the collection of 2,828 clones. Importantly, the mean Dox ratio for the 2,828 clones was significantly different from the mean of unsorted cells (3.02 versus 1.00), indicating that the sorting and the regulated expression of cDNA libraries worked efficiently. Interestingly, a number of clones gave a Dox ratio that was \< 1. This implies that these clones may express proteins that positively regulate TCR function. While we have focused on the dominant-negative regulators of T-cell signaling in this report, we expect that a fuller investigation of these clones would be warranted.

###### 

Click here for additional data file

###### Additional data file 5

**(a)** Details of selected cell clones from which various TCRβ hits were identified. Nineteen randomly chosen cell clones that contributed to various TCRβ hits and five randomly chosen cell clones that contributed to various other hits (given in parentheses) were left unstimulated, or stimulated with C305 (anti-TCRβ), anti-CD3 or PMA for 24 h. CD69 surface expression was measured with anti-CD69-APC before and after stimulation, whereas CD3 surface expression was measured only with resting cells. The fold induction was obtained by dividing CD69 geometric mean after stimulation by that of the same clone before stimulation. In control Jurkat-tTA cells, C305 gave a much stronger induction of CD69 expression (47.5-fold) than did anti-CD3 (6.4-fold). With cells identified to have a CD69-inhibitory phenotype and later shown to harbor other hits such as Csk, Nucleolin, SHP-1, Moesin, and Ku70, C305 stimulation was severely compromised (1.5-2.6-fold). Nevertheless, with the exception of one, these cells responded better to C305 stimulation than to anti-CD3 stimulation. With cells harboring the TCRβ hits, however, a reverse trend was seen. With these cells, anti-CD3 stimulation gave a higher induction of CD69 expression than did C305 stimulation. This observation supported our hypothesis that various TCRβ hits may compete with the endogenous Jurkat clonotypic TCRβ to form a new TCR-CD3 complex that is no longer recognized by C305 but may still be recognized by anti-CD3. **(b)** FACS data for four clones harboring TCRβ hits. Left panels are CD3 staining patterns (filled peaks). Central panels are CD69 histograms before (thin lines) and after (thick red lines) C305 stimulation. Right panels are CD69 histograms before (thin lines) and after stimulation with anti-CD3 (thick lines) or PMA (dashed lines).

###### 

Click here for additional data file

###### Additional data file 6

Summary of the genetic screen for inhibitors of TCR-induced CD69 expression.

###### 

Click here for additional data file

###### Additional data file 7

Diagrams of proteins predicted from the cDNA inserts and those from the corresponding wild-type genes are shown above the histograms. Each histogram shows the Dox-regulatable phenotype of the original cell clones. These original cell clones were grown in the presence or absence of Dox for 6 days and then stimulated overnight with the anti-TCR antibody. Cells were stained with anti-CD69-APC and analyzed by FACS. The filled peaks indicate CD69 expression level in the absence of Dox, when the cDNA hits were expressed. The open peaks indicate CD69 expression level in the presence of Dox, when the cDNA hits were not expressed. The Dox ratio is shown above the histograms. The following cDNA hits are shown: **(a)** Syk; **(b)** SHP-1 (PTP1C); **(c)** PAG; **(d)** A-Raf-1; **(e)** TCPTP; **(f)** IL-10Ra; **(g)** integrin a2; **(h)** SH2-B; **(i)** GG2-1; **(j)** moesin; and **(k)** vimentin. Open file for more details.
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Click here for additional data file

###### Additional data file 8

Stronger CD69 inhibitory phenotypes correlate with higher expression levels of the cDNA hits. The cDNA inserts such as **(a)** Lck and PLCγ1 or **(b)** TCPTP and Grb7 were subcloned in front of IRES-GFP in the Tet-regulated retroviral vector pTRA-IRES-GFP where the expression of hits was positively correlated with the expression of GFP. After retroviral infection, the Jurkat-tTA cells were left unstimulated (left panels), or stimulated with C305 (300 ng/ml, center panels) or PMA (5 ng/ml, right panels), and analyzed by FACS for CD69 induction after staining with anti-CD69-APC. The dot plots show CD69 expression along the *y* axis and GFP expression along the *x* axis. A diagonal shape of the dots in C305-stimulated samples indicates that cells expressing higher GFP have a lower CD69 induction (for Lck, PLCγ1 and TCPTP). Other hits (except Grb7) showed the same trend. In addition, all of the hits, with the exception of A-Raf-1, had no inhibitory effect on PMA induction of CD69 expression, suggesting that they affect membrane-proximal signaling.

A dozen or so hits did not confer CD69 inhibition when transferred to naïve Jurkat cells. There may be a few reasons for this observation. The hits may be false positives from the genetic screen. They may, on the other hand, be genuine (positive) hits from the screen. In this case a lack of phenotype upon transferring the cDNA hits to naïve Jurkat cells could result from one or a combination of the following reasons: first, the hit may be inserted in a favorable chromosomal region that allowed for high-level expression whereas the subclone in front of IRES-GFP has a compromised expression level correlating to the lack of phenotype on transfer; second, the hit may contribute to the CD69-inhibition phenotype in the original cell clone where its chromosomal integration may also accidentally disrupt a locus important for CD69 upregulation; third, there may be more than one retroviral insert in the original cell clone where the CD69-inhibition phenotype was seen, and one of them was cloned and listed in Table 1, but perhaps such a clone alone was not sufficient to confer CD69 inhibition phenotype. Given the above circumstances, it is quite possible that the hits that failed to produce a transfer phenotype may still be somehow important to TCR signal transduction leading to CD69 upregulation.

###### 

Click here for additional data file
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![Cell-line and assay development. **(a)**ZAP70 KI and ZAP70 SH2 (N+C) were subcloned in front of the internal ribosome entry site (IRES), followed by GFP, in the Tet-regulated retroviral vector (pTRA-IRES-GFP). **(b)**After infecting tTA-expressing Jurkat (4D9\#32) cells with retroviral constructs containing IRES-GFP, ZAP70 KI-IRES-GFP, or ZAP70 SH2 (N+C)-IRES-GFP, cells were left unstimulated or stimulated with anti-TCR antibody for 24 h. CD69 expression was analyzed after gating on the GFP-positive population (infected population, boxed in R1). The dashed line and the thin line on the graphs indicate cells infected with IRES-GFP (vector) before and after TCR stimulation, respectively, and the thick line indicates cells infected with ZAP70 KI-IRES-GFP (top panel) or ZAP70 SH2 (N+C)-IRES-GFP (bottom panel), both after TCR stimulation. **(c)**After infecting Jurkat-tTA (4D9\#32) cells with retroviral vector alone or vector containing ZAP70 SH2 (N+C)-IRES-GFP, cells were cultured without (top panels) or with (bottom panels) Dox for 6 days, and then left unstimulated or stimulated with anti-TCR antibody for 24 h. The box R1 indicates GFP-positive cells. CD69 expression was analyzed for the entire cell population. The dashed line and the thin line indicate cells infected with vector before and after TCR stimulation, respectively, and the thick line indicates cells infected with vector containing ZAP70 SH2 (N+C)-IRES-GFP after TCR stimulation. **(d)**The Jurkat-tTA (4D9\#32) cells containing different retroviral constructs (shown above the lanes) were cultured in the absence (-) or presence (+) of Dox, and whole-cell lysates were prepared. Lysates were loaded (100 μg per lane) and analyzed by western blotting using anti-ZAP70 antibody (Upstate Biotechnology, Waltham, USA). The top ZAP70 band included endogenous (- and + Dox) as well as retrovirally expressed ZAP70 (-Dox only), whereas the bottom ZAP70 band contained only retrovirally expressed truncated ZAP70 SH2 (N+C).](1475-4924-2-21-1){#F1}

![Screen for inhibitors of TCR-activation-induced CD69 expression. **(a)**Cells (3.5 × 10^8^) were infected with pTRA-cDNA libraries. Single-cells were cloned after at least four consecutive sortings of the CD69^low^CD3^+^phenotype. **(b)**Cells (7.1 × 10^8^) were sorted with high-speed flow sorters (MoFlo) after stimulation and staining with anti-CD69-APC and anti-CD3-PE. The sort gate was set at the equivalent of 1% of satellite control cells that were stimulated but never flow-sorted (shown as R2) to enrich for the CD69^low^CD3^+^phenotype. After sorting, the desired cells were allowed to rest for 6 days before another round of stimulation and sorting. **(c)**Cells were split into two populations after the third round of sorting. One half of the cells were grown in the absence of Dox (top left dot-plot) and the other half in the presence of Dox (top right dot-plot). Six days later, CD69 expression was compared following anti-TCR stimulation. The dashed line indicates CD69 level without Dox and the solid line with Dox (bottom graph).](1475-4924-2-21-2){#F2}

![Identification of clones with desired phenotype. **(a)**Individual clones were grown in the presence (open peaks) or absence (filled peaks) of Dox for 6 days and then stimulated to examine CD69 expression by FACS. The \'Dox ratio\' was defined as the ratio of CD69 geometric mean fluorescent intensity in the presence of Dox divided by CD69 geometric mean fluorescent intensity in the absence of Dox and is indicated in parentheses following the clone number. **(b)**DNA oligonucleotide primers specific to the library vector (BstXTRA5G and BstXTRA3D, not to scale) were used in RT-PCRs to recover the cDNA inserts from cell clones. The RT-PCR products were analyzed in agarose gel followed by ethidium blue staining. Data from representative clones are shown alongside the 1 kb DNA molecular weight ladder (M~r~) from New England BioLabs (Beverly, USA).](1475-4924-2-21-3){#F3}

![Transfer of selected hits from the functional genetic screen to naïve Jurkat-tTA (4D9\#32) cells. Diagrams of proteins predicted from the cDNA inserts and those from the corresponding wild-type genes are shown above the histograms. The left panel of histograms shows the phenotype of the original cell clones in the presence (open peaks) or absence (filled peaks) of Dox as analyzed in Figure [3a](#F3){ref-type="fig"}. The Dox ratio is indicated. The right top and bottom panels of histograms show the phenotypes after expressing the cDNA inserts (followed by IRES-GFP) in a naïve Jurkat-tTA population. After retroviral infection, the Jurkat-tTA (4D9\#32) cells were either stimulated with the anti-TCR antibody (solid line) or left unstimulated (dashed line), and analyzed by FACS for CD69 induction after staining with anti-CD69-APC. The top right histogram in each group analyzed GFP-negative cells, which did not express the cDNA hit, whereas the bottom right histogram in each group analyzed GFP-positive cells, which expressed the cDNA hit. The following cDNA hits are shown: **(a)**ZAP70; **(b)**Lck; **(c)**PLC31; **(d)**EDG1; **(e)**PAK2; **(f)**Grb7; **(g)**TRAC-1.](1475-4924-2-21-4){#F4}

![EDG1, PAK2, Grb7 and TRAC-1 expression in normal human tissues and lymphocyte subsets. **(a,b)**Northern blot analysis using multi-tissue blot (Clontech). The following genes are shown: (a) EDG1 and PAK2; (b) Grb7 and TRAC-1. **(c-f)**Semi-quantitative PCR analysis of gene expression in lymphocyte subsets. The cDNA templates were obtained from CD4^+^T cells, CD8^+^T cells, CD19^+^B cells, or CD14^+^monocytes (human blood fractions MTC panel from Clontech). Specific target primers or control primers were used in PCR reactions. The following genes are shown: **(c)**EDG1; **(d)**PAK2; **(e)**Grb7; **(f)**TRAC-1.](1475-4924-2-21-5){#F5}

![The cDNA hits from the functional genetic screens inhibited activation in human primary T lymphocytes. **(a)**Human PBL were cultured with anti-CD3 and anti-CD28 for 3 days and then infected with the retroviral CRU5-GFP vector, whereby GFP was expressed from the constitutively active retroviral LTR promoter. Cells were stained with anti-CD3-APC, or with anti-CD4-PE and anti-CD8-APC antibodies and analyzed by FACS. The percentage of cells in each quadrant is shown. **(b)**Human primary T lymphocytes were infected with vector alone (CRU5-GFP and CRU5-IRES-GFP or CIG) or with the CIG vector expressing the Lck, PLCγ1, EDG1 and PAK2 hits. The infection rate was monitored by the percentage of GFP-positive cells (marked with M1). The geometric mean of GFP for cells in marker M1 was shown above the marker line. **(c)**Infected primary T lymphocytes were allowed to rest and then sorted to give rise to GFP-negative (open bars) and GFP-positive (filled bars) populations. Equal numbers of cells were cultured without stimulation, with anti-CD3 or anti-CD3 plus anti-CD28 antibodies, or with PMA plus ionomycin. Then, 40 h later the culture supernatants were harvested and assayed for IL-2 production by ELISA. Note the difference in the scales and the standard deviations with cells stimulated with anti-CD3 plus anti-CD28, or with PMA plus ionomycin (lower panels) compared to the upper panels.](1475-4924-2-21-6){#F6}

###### 

Overview of identified molecular targets

  Gene                                     Domain homology                      Direction   Accession number\*   Relative to ORF\*   Frequency\*   Phenotype transfer
  ---------------------------------------- ------------------------------------ ----------- -------------------- ------------------- ------------- --------------------
  **Known to function in TCR pathway**                                                                                                             
  TCRβ                                     Receptor                             Sense       Numerous             Partial             46            On hold
  ZAP70                                    Tyrosine kinase                      Sense       L05148.1             -147, +787 nt       12            Yes
  ZAP70 (long)                             Tyrosine kinase                      Sense       L05148.1             -21, +809 nt        17            TBD
  Syk                                      Tyrosine kinase                      Sense       L28824.1             -27, +1012 nt       2             Yes
  Lck                                      Tyrosine kinase                      Sense       U23852.1             -59, +799 nt        4             Yes
  PLCγ1                                    Tyrosine kinase                      Sense       NM_002660.1          +1409, +2282 nt     3             Yes
  SHP-1/PTP1C                              Protein-tyrosine phosphatase         Sense       X62055.1             +472, \>+2021 nt    1             Yes
  Csk                                      Tyrosine kinase                      Sense       NM_004383.1          -55, +1285 nt       1             TBD
  PAG                                      Transmembrane adaptor                Sense       NM_018440.2          -237, +644 nt       1             Yes
  Nucleolin                                RNA-binding                          Sense       NM_005381.1          -136, +479 nt       1             No
                                                                                                                                                   
  **Enzymes and receptors**                                                                                                                        
  TCPTP/PTPN2                              Protein-tyrosine phosphatase         Sense       NM_002828.1          -58, +1108 nt       20            Yes
  PAK2                                     p21-activated kinase 2               Sense       NM_002577.1          -50, +339 nt        18            Yes
  PAK2 (long)                              p21-activated kinase 2               Sense       NM_002577.1          -42, +670 nt        1             Yes
  A-Raf-1                                  Serine/threonine kinase              Sense       X04790.1             -4, +456 nt         5             Yes
  EDG1                                     G-protein-coupled receptor           Sense       NM_001400.2          \<-244, +942 nt     4             Yes
  EDG1 (long)                              G-protein-coupled receptor           Sense       NM_001400.2          \<-244, +1037 nt    1             TBD
  TRAC-1                                   RING finger ubiquitin ligase         Sense       NM_017831.1          -254, +510 nt       1             Yes
  IL-10Rα                                  Receptor                             Sense       NM_001558.1          +689, +1350 nt      1             Yes
  Integrin α~2~                            Receptor                             Sense       NM_002203.2          +3348, +3914 nt     1             Yes
  Enolase 1α                               Phosphopyruvate hydratase            Sense       NM_001428.1          +703, +1374 nt      2             No
  DUSP1                                    Dual-specificity phosphatase         Sense       NM_004417.2          +817, +1112 nt      1             No
  KIAA0251                                 Pyridoxal-dependent decarboxylase    Sense       D87438.1             nt 2098-2370^†^     1             No
                                                                                                                                                   
  **Adaptors and transcription factors**                                                                                                           
  Grb7                                     Adaptor                              Sense       NM_005310.1          +1268, +1912 nt     3             Yes
  GG2-1                                    TNF-induced protein                  Sense       AF070671.1           -97, +1795 nt       2             Yes
  SH2-B                                    Adaptor                              Sense       AF227968.1           +1352, +1960 nt     1             Yes
  RERE                                     Transcriptional factor               Sense       AB036737.1           +914, +1202 nt      3             No
  SudD                                     Serine/threonine rich                Sense       NM_003831.1          -93, +413 nt        1             No
  Ku 70                                    DNA-PKc subunit                      Sense       S38729.1             +1026, +2069 nt     1             No
  Novel (130 amino acids; no homology)     Unknown                              Sense       AC005321.1           nt 33543-33938^‡^   1             No
  Novel signaling molecule                 GYF domain                           Sense       NM_022574.1          +1, +121 nt         1             No
  SCAMP2                                   Secretory carrier membrane protein   Sense       AF005038.2           -5, +833 nt         1             No
  KIAA1228                                 C2 domain (Ca^2+^- or IP-binding)    Sense       AB033054.2           nt 1439-2163^†^     1             No
  EST from clone 2108068                   LPP20 lipoprotein precursor          Sense       Al357532.1           Novel isoform       1             No
  RNH                                      Ribonuclease/angiogenin inhibitor    Sense       NM_002939.1          -22, +713 nt        1             No
                                                                                                                                                   
  **Cytoskeleton**                                                                                                                                 
  Moesin                                   Moesin                               Sense       NM_002444.1          -93, +1534 nt       1             Yes
  Vimentin                                 Intermediate filament                Sense       NM_003380.1          -98, +374 nt        1             Yes
                                                                                                                                                   
  **Others**                                                                                                                                       
  Alu repeat                                                                                                                         5             On hold
  CpG island? (clone 550H1)                                                                 AL035420.1                               1             On hold
  IgG2 heavy chain                         Ig superfamily                       Sense                            Partial             1             On hold
  Ig light chain                           Ig superfamily                       Sense                            Partial             1             On hold
  18S rRNA                                                                      Sense       M10098.1             Partial             2             On hold
  28S rRNA                                                                      Sense                            Partial             1             On hold

\*For each identified clone, the GenBank database \[[@B51]\] accession number is given, followed by the first and last nucleotide (nt) positions relative to the initiation codon (ATG being the +1, +2, +3 nts, respectively); Frequency indicates the number of original cell clones expressing the specific hit. ^†^Relative to the EST itself because the start codon is not identified. ^‡^Relative to the genomic clone itself. Ig, Immunoglobulin; TBD, to be determined.
